Journal of Cutaneous Immunology and Allergy最新文献

Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, is characterized by the proliferation of small- to medium-sized atypical, usually CD4+ T cells in the skin.¹ Mycosis fungoides with large-cell transformation (LCT) is an aggressive subtype defined by the presence of large cells comprising >25% of the lesion infiltrate or the presence of microscopic nodules of large cells. Large-cell transformation occurs in 20%–55% of advanced MF cases and is often a histological marker of poor prognosis and is associated with a mean 5-year survival rate of <20%.¹ Herein, we present a patient with MF-LCT in its early stage that was successfully treated with brentuximab vedotin (BV), an anti-CD30 antibody.

A woman in her early 30s had erythema with pruritus and pigmentation on her trunk and thighs for 3 years (Figure 1A). Following subsequent histopathological diagnosis as MF (negative CD30+ lymphocytes at this time), she was successfully treated with topical steroids and ultraviolet therapy and showed no progression for approximately 10 years. In her early 40s, the rash slowly expanded and was treated with bexarotene (450–150 mg/day). One year later, the eruption intensified, with erythema observed on 40% of the body and multiple skin tumors of ≥1 cm (Figure 1B,C). Histopathology and immunohistochemistry of the tumors confirmed infiltration with CD3+, CD4+, CD5+, CD8+ (CD4/CD8: 10/1), CD30+, and CD20− lymphocytes, and CD30+ lymphocytes with large nuclei comprised 30% of the infiltrate (Figure 1D,E). The patient's complete blood count was normal, and the peripheral blood smear was negative for Sézary cells. Bone marrow examination showed no infiltration of atypical lymphocytes. No lymph node metastasis was found on positron emission tomography–computed tomography. Mycosis fungoides stage IIB (T3M0N0) with CD30+ LCT was diagnosed, and BV treatment was initiated instead of bexarotene. After three doses, the eruption area decreased, and the nodules became flattened (Figure 1E,F). After a total of 16 BV treatments, the only side effect observed was mild sensory polyneuropathy.

Brentuximab vedotin is an antibody–drug conjugate (ADC) in which monomethyl auristatin E (MMAE), which has cytotoxic activity, and an anti-CD30 IgG1-type chimeric antibody are linked via a protease-cleavable linker. The ADC inhibits tumor growth by first binding to CD30+ cells. Then, after being taken up into the cells as an ADC–CD30 complex, it releases MMAE through a proteolytic reaction. The free MMAE further inhibits microtubule formation and induces cell cycle arrest and apoptosis.² In a clinical trial of 30 patients (MF and Sézary syndrome), the response rate for BV was 70%, wherein 54% of the respondents were free of disease progression for 1 year³; however, the information on MF-LCT is still limited.

Bhari N et al. reported that the survival p

We herein report a case of allergic contact dermatitis (ACD) caused by Dermabond® Advanced, which was diagnosed by a patch test using SurgiSeal® (Nitcho Kogyo, Tokyo, Japan) as a control. A difference in the temperature increase at the time of application suggested that temperature may be a risk factor for sensitization.

While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug-associated retinopathy has become an emerging adverse event. We present two Japanese men with advanced melanoma who developed visual impairment due to serous retinal detachments (SRDs) with cystoid macular edema (CME) immediately after initial administration of encorafenib/binimetinib, a BRAF and MEK inhibitor. One case had drug-intolerable retinopathy on repeat dosing. Both cases were switched to another BRAF/MEK inhibitors, dabrafenib/trametinib, with no recurrence of SRDs. Co-existing CME may be a confounding risk for the early development of SRDs with encorafenib/binimetinib therapy, providing attention during drug administration.

We report a case of rheumatoid arthritis who developed cutaneous diffuse large B-cell lymphoma during methotrexate (MTX) monotherapy with prompt resolution after discontinuation of the drug. Our literature review of over 100 reported Japanese cases revisited the potential risk of treatment resistance and/or repeated recurrence of lymphomas, particularly in cases that were unresponsive to the withdrawal of MTX or received a higher cumulative dose.

We have experienced a case of SWSL involving significant gastrointestinal erosion that occurred after TMP-SMX medication. For accurate diagnosis and prompt treatment of complications, it is essential to be aware of the possibility of this phenomenon.

An 81-year-old Japanese man presented with a history of recurrent eyelid swelling and purpura on the face, neck, and limbs. Because the initial clinical presentation was angioedema alone, the patient was treated with an H1-receptor antagonist and tranexamic acid as for an idiopathic angioedema. The patient also experienced dyspnea simultaneously with edema on the face and limbs and was thus taken to the emergency room, where laryngeal edema was confirmed on laryngeal fiber. A good response to hydrocortisone injection was observed in the patient. ACE inhibitors were never prescribed for the patient, and there was no family history of angioedema. Laboratory data indicated normocomplementemia, and skin biopsies revealed leukocytoclastic vasculitis. Therefore, the patient was diagnosed with NUV. Following hospitalization, the patient experienced appetite loss and the CRP level increased, presenting with thickening and stranding around colon tissues on abdominal CT. These symptoms responded well to prednisone treatment. Given that the initial clinical manifestation of the current case was mainly angioedema, physicians should consider that angioedema may in rare cases be diagnostic for UV.

The case of a widespread erythematous drug eruption brought on by favipiravir is described here. Patch tests and the drug lymphocyte transformation test (LTT) both indicated a positive reaction. Since COVID-19 patients take many medications, the potential for a drug eruption must be taken into account when diagnosing a rash.

We present a case of Generalized pustular psoriasis (GPP) presented with SARS-CoV-2 infection under the control of secukinumab. Mutation analysis revealed a heterogeneous c.28C>T (p.Arg10X) mutation in IL36RN. Mutation analysis should be considered to enable preparation for biologic therapy to treat intractable flare-ups.